Market Intelligence for Neutrophil Serine Protease Inhibitors & High-Purity Reagents for Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CTSG drug discovery. Select your modality below for selectivity screening and inhibitor validation.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Enzyme | CTSG Recombinant Protein (Active). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed for native folding. | View CTSG Products |
| Control Mutant | CTSG Catalytic Dead Mutant (S195A). Active site serine mutated to alanine for negative control assays. Theoretical MW verified. | View CTSG Products |
| Gene Delivery | CTSG Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. | View CTSG Products |
| Benchmark Ab | Anti-CTSG Recombinant Antibody (Research Grade). Sequence Verified Positive Control. | View CTSG Products |
| Selectivity Panel – ELANE | Neutrophil Elastase (ELANE) Protein. High purity (>95%), HEK293 expressed. For counter-screening. | View ELANE Products |
| Selectivity Panel – PRTN3 | Proteinase 3 (PRTN3) Protein. High purity (>95%), HEK293 expressed. For counter-screening. | View PRTN3 Products |
| Selectivity Panel – CTSB | Cathepsin B (CTSB) Protein. Cysteine protease control for selectivity profiling. | View CTSB Products |
| Validator | CTSG siRNA Set. For knockdown verification and specificity controls. | View CTSG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Serine Protease Selectivity (CTSG vs ELANE/PRTN3/CTSB) | High-purity human ELANE, PRTN3, and CTSB proteins available with matched endotoxin levels (<1EU/µg) for parallel kinetic studies. |
| Enzymatic Activity Standardization | Sequence-verified active CTSG with theoretical MW confirmation; Catalytic triad integrity assessed by zymography; catalytically inactive mutant (S195A) available as negative control. |
| Control Reagents (Lack of Controls) | Research-grade benchmark antibodies and validated siRNA for assay standardization. |
| False Positive/Compound Interference | High-purity protein preparations minimize contaminant interference; catalytic dead mutant included for mechanism confirmation. |
Live CTSG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Inhibitor Research
- Selectivity & Resistance Mechanisms
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Cathepsin G is experiencing renewed interest as the pharmaceutical industry pivots from broad-spectrum anti-inflammatories to precision neutrophil biology modulators. Historically pursued for chronic obstructive pulmonary disease (COPD) and cystic fibrosis, CTSG inhibitors are now entering clinical evaluation for severe inflammatory conditions where neutrophil extracellular traps (NETs) drive pathology, including acute respiratory distress syndrome (ARDS) and autoimmune vasculitis. The current landscape is dominated by small molecule active site inhibitors, with emerging interest in allosteric modulators and biologic inhibitors (e.g., alpha-1 antitrypsin mimetics). As first-generation reversible inhibitors advance to Phase II, the next wave of R&D focuses on lung-targeted delivery systems and dual-specificity inhibitors that spare elastase (ELANE) to preserve lung defense mechanisms while dampening CTSG-mediated tissue damage. Additionally, the role of CTSG in cardiovascular thrombotic events is gaining attention, expanding the therapeutic scope beyond respiratory and inflammatory indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Vertex Pharmaceuticals, Early-stage biotechs | COPD, Cystic Fibrosis, Neutrophilic Dermatoses | Selectivity Panel (CTSG vs ELANE/PRTN3) with kinetic constants determination |
| Allosteric Modulator | Academic consortia, Preclinical programs | Autoimmune Vasculitis | Conformational binding assays (SPR/BLI) requiring high-purity, correctly folded protein |
| Biologic Inhibitor | Protein engineering firms | Acute Lung Injury | Epitope mapping against active site vs exosite regions; Competition assays |
| Targeted Delivery | Specialized inhalation companies | Bronchiectasis | Stability assays at high concentration (viscosity testing) for nebulization formulations |